Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Schering-Plough

- PMLiVE

Triple therapy ‘might cure hep C in six weeks’

Phase II trials shows promise for Merck and Gilead drugs

- PMLiVE

EMG appoints Merck and Boehringer directors as new officers

David Garmon-Jones is new chair and Zinta Krumins is vice chair

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Merck & Co plays catch-up with osteoporosis data for odanacatib

Says study shows significant reduced risk of osteoporotic symptoms

- PMLiVE

FDA rejects Merck muscle relaxant drug once again

Regulator still has hypersensitivity concerns about Bridion

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

- PMLiVE

Merck resubmits anaesthesia drug Bridion in US

FDA previous the neuromuscular reversal agent in 2008

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links